All filters
Slidesets
(Abstract) Case Control study of the oral microbiome in HIV uninfected individuals compared to HIV positive individuals before and after HAART | D. Malamud
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
The “Window of Opportunity”: Harnessing the Pediatric Immune Landscape for Life-Long Vaccine- Elicited Protection | Sallie Permar, MD, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
(Abstract) Enteric virome analysis of non-invasive samples from gorillas by next-generation sequencing and association with SIV infection | M. D’arc
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
Functional Role of Gut Microbiota in Chronic Liver Disease | Gary Wu, MD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
The Mycobiome and How it Influences Disease | Mahmoud Ghannoum, PhD, MBA
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
Live Biotherapeutics: How the Vaginal Microbiome Can be Modified to Prevent HIV Infection | Laurel Lagenaur, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
The NIH’s human microbiome project | Lita Proctor, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
The Human Microbiome and Cancer: New Opportunities For Population Studies | Emily Vogtmann, PhD, MPH
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Slidesets
Oral microbiota in relation to HIV infection and oral infection in perinatally HIV-infected adolescents | Bruce Paster, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2016
Meeting
European HIV Clinical Forum 2016
Slidesets
Impact on: Adherence/tolerability - Ian McGowan, MB, ChB, DPhil, MD, FRCP
Presented at:
European HIV Clinical Forum 2016
Slidesets
Impact on: Virology/Resistance - Daniel Kuritzkes, MD
Presented at:
European HIV Clinical Forum 2016
Slidesets
A Multicenter Observational Study on the Efficacy and Tolerability of Dolutegravir combined with Tenofovir/Emtricitabine or Abacavir/Lamivudine as a Switch Strategy for HIV-1 Pos. ART-exp. Patients with Stable Viral Suppression- Alberto Borghetti
Presented at:
European HIV Clinical Forum 2016
Slidesets
Impact on: Pharmacology – penetration to sanctuary sites and drug-drug interactions - Courtney Fletcher, PharmD
Presented at:
European HIV Clinical Forum 2016
Slidesets
Virological failure even at low levels of viremia can be associated to integrase strand-transfer inhibitors resistance in HIV-1 infected patients - Benet Garrabé
Presented at:
European HIV Clinical Forum 2016
Slidesets
French National survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology network) - Vincent Calvez
Presented at:
European HIV Clinical Forum 2016
Slidesets
An Italian case of transmitted integrase inhibitor resistance in a drug-naïve patient: a refined analysis by ultra-deep-454 pyrosequencing - Ada Bertoli
Presented at:
European HIV Clinical Forum 2016
Slidesets
Clinical Case Presentations – How to manage drug - drug interactions - the practice - Anna Maria Geretti, MD, PhD, FRCPath
Presented at:
European HIV Clinical Forum 2016
Slidesets
Clinical Utility of Integrase Inhibitors during pregnancy - Saye Khoo, MD, PhD
Presented at:
European HIV Clinical Forum 2016
Slidesets
Virological response of HIV-infected-patients virologically-suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score - Diane Descamps
Presented at:
European HIV Clinical Forum 2016
Slidesets
Lamivudine plus either Atazanavir/ritonavir, Darunavir/ritonavir or Dolutegravir as switch strategies in HIV-positive, virologically-suppressed patients: a comparison - Alberto Borghetti
Presented at:
European HIV Clinical Forum 2016
Slidesets
Switching from combination antiretroviral therapy (cART) to dolutegravir (DTG) monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO) - Ingeborg Wijting
Presented at:
European HIV Clinical Forum 2016